Astrazeneca Pharma India Ltd
NSE: ASTRAZEN BSE: 506820
₹8760
(-0.63%)
Fri, 13 Mar 2026, 05:38 pm
Market Cap220.04B
PE Ratio109.01
Dividend0.37
Health Technology
Pharmaceuticals: Major
24.5KAstrazeneca Pharma India Analysis
dividend
- AstraZeneca Pharma India is not paying a notable dividend for India, therefore no need to check if the payments are increasing.
- No need to calculate the sustainability of AstraZeneca Pharma India's dividends as it is not paying a notable one for India.
- AstraZeneca Pharma India is not paying a notable dividend for India, therefore no need to check if the payments are stable.
- AstraZeneca Pharma India's pays a lower dividend yield than the bottom 25% of dividend payers in India (0.76%).
- AstraZeneca Pharma India's dividend is below the markets top 25% of dividend payers in India (3.08%).
health
- AstraZeneca Pharma India is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
- AstraZeneca Pharma India is profitable, therefore cash runway is not a concern.
- AstraZeneca Pharma India is profitable, therefore cash runway is not a concern.
- AstraZeneca Pharma India has no debt, it does not need to be covered by operating cash flow.
- AstraZeneca Pharma India has no debt, it does not need to be covered by short term assets.
- AstraZeneca Pharma India's cash and other short term assets cover its long term commitments.
- AstraZeneca Pharma India has no debt compared to 5 years ago when it was 0.4%.
- AstraZeneca Pharma India has no debt, therefore coverage of interest payments is not a concern.
- AstraZeneca Pharma India has no debt.
- High level of physical assets or inventory.
management
- The tenure for the AstraZeneca Pharma India board of directors is about average.
- Gagan's remuneration is about average for companies of similar size in India.
- Gagan's compensation has been consistent with company performance over the past year, both up more than 20%.
- The average tenure for the AstraZeneca Pharma India management team is over 5 years, this suggests they are a seasoned and experienced team.
misc
- AstraZeneca Pharma India is not covered by any analysts.
- AstraZeneca Pharma India has significant price volatility in the past 3 months.
past
- AstraZeneca Pharma India has delivered over 20% year on year earnings growth in the past 5 years.
- AstraZeneca Pharma India has significantly improved its use of capital last year versus 3 years ago (Return on Capital Employed).
- AstraZeneca Pharma India's earnings growth has exceeded the IN Pharmaceuticals industry average in the past year (32.2% vs 22.7%).
- AstraZeneca Pharma India's 1-year earnings growth is less than its 5-year average (32.2% vs 40.9%)
- AstraZeneca Pharma India used its assets less efficiently than the IN Pharmaceuticals industry average last year based on Return on Assets.
- AstraZeneca Pharma India has not efficiently used shareholders’ funds last year (Return on Equity less than 20%).
value
- 506820 outperformed the Pharmaceuticals industry which returned 26.7% over the past year.
- 506820 outperformed the Market in India which returned -14.5% over the past year.
- BSE:506820 is up 15.3% outperforming the Pharmaceuticals industry which returned 6.8% over the past month.
- BSE:506820 is up 15.3% outperforming the market in India which returned 8% over the past month.
- AstraZeneca Pharma India's share price is above the future cash flow value, it's not available at a moderate discount (< 20%).
- AstraZeneca Pharma India's share price is above the future cash flow value, it's not available at a substantial discount (< 40%).
- AstraZeneca Pharma India is overvalued based on assets compared to the IN Pharmaceuticals industry average.
- AstraZeneca Pharma India is overvalued based on earnings compared to the IN Pharmaceuticals industry average.
- AstraZeneca Pharma India is overvalued based on earnings compared to the India market.
Open Your Free Demat Account Now!
Facebook
Twitter
Instagram
LinkedIn
Youtube
Calculators
Popular Calculators
Group Stocks
Pocketful Fintech Capital Private Limited (CIN U65999DL2021PTC390548) | The SEBI Registration No. allotted to us is INZ000313732. NSE Member Code: 90326 | BSE Member Code: 6808 | MCX Member Code: 57120 DP | CDSL: 12099800